4-BenzyloxyindoleCAS# 20289-26-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 20289-26-3 | SDF | Download SDF |
| PubChem ID | 88465 | Appearance | Powder |
| Formula | C15H13NO | M.Wt | 223.3 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 4-phenylmethoxy-1H-indole | ||
| SMILES | C1=CC=C(C=C1)COC2=CC=CC3=C2C=CN3 | ||
| Standard InChIKey | LJFVSIDBFJPKLD-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C15H13NO/c1-2-5-12(6-3-1)11-17-15-8-4-7-14-13(15)9-10-16-14/h1-10,16H,11H2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
4-Benzyloxyindole Dilution Calculator
4-Benzyloxyindole Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.4783 mL | 22.3914 mL | 44.7828 mL | 89.5656 mL | 111.957 mL |
| 5 mM | 0.8957 mL | 4.4783 mL | 8.9566 mL | 17.9131 mL | 22.3914 mL |
| 10 mM | 0.4478 mL | 2.2391 mL | 4.4783 mL | 8.9566 mL | 11.1957 mL |
| 50 mM | 0.0896 mL | 0.4478 mL | 0.8957 mL | 1.7913 mL | 2.2391 mL |
| 100 mM | 0.0448 mL | 0.2239 mL | 0.4478 mL | 0.8957 mL | 1.1196 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 8-Hydroxy-3,5,7,3',4',5'-hexamethoxyflavone
Catalog No.:BCN1506
CAS No.:202846-95-5
- Rosmarinic acid
Catalog No.:BCN5893
CAS No.:20283-92-5
- Safinamide Mesylate
Catalog No.:BCC2320
CAS No.:202825-46-5
- Ralfinamide mesylate
Catalog No.:BCC7844
CAS No.:202825-45-4
- BMS 191011
Catalog No.:BCC7448
CAS No.:202821-81-6
- Licoagrochalcone A
Catalog No.:BCC8197
CAS No.:202815-28-9
- Orexin B (mouse)
Catalog No.:BCC5766
CAS No.:202801-92-1
- 4-Methoxycoumarine
Catalog No.:BCN6536
CAS No.:20280-81-3
- Homodihydrocapsaicin I
Catalog No.:BCN7844
CAS No.:20279-06-5
- Forsythenside A
Catalog No.:BCN6440
CAS No.:202721-09-3
- Nicotinamide N-oxide
Catalog No.:BCN1969
CAS No.:1986-81-8
- 3α-Bis-(4-fluorophenyl) methoxytropane hydrochloride
Catalog No.:BCC6846
CAS No.:202646-03-5
- 7-Benzyloxyindole
Catalog No.:BCC8778
CAS No.:20289-27-4
- glucagon receptor antagonists 3
Catalog No.:BCC1595
CAS No.:202917-17-7
- glucagon receptor antagonists 2
Catalog No.:BCC1594
CAS No.:202917-18-8
- Conantokin-R
Catalog No.:BCC5980
CAS No.:202925-60-8
- NF 340
Catalog No.:BCC7785
CAS No.:202982-98-7
- NF 279
Catalog No.:BCC6964
CAS No.:202983-32-2
- Aporheine
Catalog No.:BCN4802
CAS No.:2030-53-7
- Clofazimine
Catalog No.:BCC4651
CAS No.:2030-63-9
- Saponarin
Catalog No.:BCN2280
CAS No.:20310-89-8
- Solamargine
Catalog No.:BCN2305
CAS No.:20311-51-7
- Procyanidin B1
Catalog No.:BCN6314
CAS No.:20315-25-7
- Tiliroside
Catalog No.:BCN4889
CAS No.:20316-62-5
Synthetic studies of psilocin analogs having either a formyl group or bromine atom at the 5- or 7-position.[Pubmed:11824592]
Chem Pharm Bull (Tokyo). 2002 Jan;50(1):92-9.
Psilocin analogs having either a formyl group (9-12) or a bromine atom (13-18) at the 5- or 7-position have been prepared for the first time. Syntheses of 5- and 7-bromo derivatives of 4-hydroxy- (23, 24, 28) and 4-Benzyloxyindole-3-carbaldehyde (19, 25, 29, 30), 4-Benzyloxyindole-3-acetonitriles (20, 31), and 4-benzyloxy-N,N-dimethyltryptamine (32, 34, 35) have also been established.
Synthesis, pharmacology, and molecular modeling of novel 4-alkyloxy indole derivatives related to cannabimimetic aminoalkyl indoles (AAIs).[Pubmed:9313864]
Bioorg Med Chem. 1997 Aug;5(8):1591-600.
Several novel 4-alkyloxy-aminoalkyl indole derivatives 3 were synthesized from 4-Benzyloxyindole (1). Alkylation of 1 with 4-(2-chloroethyl)morpholine (NaH/HMPA) formed 2. Deprotection using palladium hydroxide on carbon/hydrogen followed by alkylation with the appropriate alkyl bromide gave the target compounds 3b-3j. In the synthesis of 3i and 3j, the appropriate alkyl bromides 13 and 17 were prepared from the commercially available 1-naphthylethyl bromide 9 using the chain lengthening sequences as shown in Scheme 3. In receptor binding assay and in vivo testing, the long chain alkoxy compounds 3g and 3h (Ki = 127 nM) showed affinity for the CB1 receptor which was approximately 16-35-fold less than that of WIN 55,225. However, the pharmacological profile of 3h mimics that of WIN 55,212. An examination of the SAR of these analogues shows that translocating the napthyl group in AAIs from the C-3 position to C-4 via an oxygen (ether linkage) decreases activity which is in contrast to previous findings that a naphthylcarbonyl at C-4 retains activity. The present work points to the importance of the role of a keto group in the interaction with the receptor. Molecular modeling work suggests that, although reasonable superposition of key structural features between delta 9-THC and AAIs can be made, the overlay is not straightforward. The present study also illustrates the difficulty in accommodating AAIs into the cannabinoid pharmacophore and it seems likely that a unique pharmacophore will need to be developed. Only then will the similarities to and differences from the classical cannabinoid pharmacophore be clearly delineated.
